[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE057581T2 - Új vegyületek és ezeket tartalmazó gyógyszerkészítmények betegségek kezelésére - Google Patents

Új vegyületek és ezeket tartalmazó gyógyszerkészítmények betegségek kezelésére

Info

Publication number
HUE057581T2
HUE057581T2 HUE18811769A HUE18811769A HUE057581T2 HU E057581 T2 HUE057581 T2 HU E057581T2 HU E18811769 A HUE18811769 A HU E18811769A HU E18811769 A HUE18811769 A HU E18811769A HU E057581 T2 HUE057581 T2 HU E057581T2
Authority
HU
Hungary
Prior art keywords
diseases
treatment
pharmaceutical compositions
novel compounds
novel
Prior art date
Application number
HUE18811769A
Other languages
English (en)
Inventor
Luke Alvey
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1720101.3A external-priority patent/GB201720101D0/en
Priority claimed from GBGB1817343.5A external-priority patent/GB201817343D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of HUE057581T2 publication Critical patent/HUE057581T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HUE18811769A 2017-12-02 2018-11-26 Új vegyületek és ezeket tartalmazó gyógyszerkészítmények betegségek kezelésére HUE057581T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1720101.3A GB201720101D0 (en) 2017-12-02 2017-12-02 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GBGB1817343.5A GB201817343D0 (en) 2018-10-25 2018-10-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
HUE057581T2 true HUE057581T2 (hu) 2022-05-28

Family

ID=64564856

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18811769A HUE057581T2 (hu) 2017-12-02 2018-11-26 Új vegyületek és ezeket tartalmazó gyógyszerkészítmények betegségek kezelésére

Country Status (23)

Country Link
US (2) US11339166B2 (hu)
EP (1) EP3717471B1 (hu)
JP (1) JP7326276B2 (hu)
KR (1) KR102720958B1 (hu)
CN (1) CN111433200B (hu)
AU (1) AU2018374456B2 (hu)
BR (1) BR112020010364A2 (hu)
CA (1) CA3084090A1 (hu)
CO (1) CO2020008066A2 (hu)
CY (1) CY1125044T1 (hu)
DK (1) DK3717471T3 (hu)
ES (1) ES2908283T3 (hu)
HU (1) HUE057581T2 (hu)
IL (1) IL274938B2 (hu)
MA (1) MA51200A (hu)
MX (1) MX2020005423A (hu)
PH (1) PH12020550725A1 (hu)
PL (1) PL3717471T3 (hu)
PT (1) PT3717471T (hu)
SG (1) SG11202004925QA (hu)
TW (1) TW201930301A (hu)
WO (1) WO2019105886A1 (hu)
ZA (1) ZA202004025B (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PL3717471T3 (pl) * 2017-12-02 2022-03-21 Galapagos Nv Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
PE20210920A1 (es) 2018-05-04 2021-05-19 Incyte Corp Formas solidas de un inhibidor de fgfr y procesos para prepararlas
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
GB201907616D0 (en) 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021146424A1 (en) * 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2021253587A1 (en) * 2020-04-08 2022-12-01 Remix Therapeutics Inc. Compounds and methods for modulating splicing
IL300205A (en) * 2020-08-05 2023-03-01 Massachusetts Gen Hospital Salt-inducible kinase inhibitors
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
KR20230107801A (ko) * 2020-09-30 2023-07-18 에프엘2022-001, 인코포레이티드 Hsd17b13 억제제 및 이의 용도
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
KR20230053049A (ko) * 2021-10-13 2023-04-21 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128280A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Derivados de bencimidazol piridina
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
WO2023164233A1 (en) * 2022-02-28 2023-08-31 Agios Pharmaceuticals, Inc. (4-benzo[d]oxazol-2-yl)-6,7-dihydro-1h-imidazo[4,5-c]pyridine-5(4h)-yl)methanone derivatives as mutant pah stabilizers for the treatment of phenylketonuria
AU2023225782A1 (en) * 2022-02-28 2024-09-12 Agios Pharmaceuticals, Inc. Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations
CN117843634A (zh) * 2022-05-24 2024-04-09 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
WO2024003208A1 (en) * 2022-07-01 2024-01-04 F. Hoffmann-La Roche Ag Imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives as sik modulators for the treatment of rheumatoid arthritis
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024141444A1 (en) * 2022-12-27 2024-07-04 F. Hoffmann-La Roche Ag New benzimidazole derivatives
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014620A1 (en) 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2320907A4 (en) * 2008-08-05 2012-09-05 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS
GB201204384D0 (en) * 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP2018526452A (ja) 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Dyrk1aの小分子抑制剤およびその使用
PL3717471T3 (pl) * 2017-12-02 2022-03-21 Galapagos Nv Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób
IL300205A (en) 2020-08-05 2023-03-01 Massachusetts Gen Hospital Salt-inducible kinase inhibitors

Also Published As

Publication number Publication date
IL274938B2 (en) 2023-05-01
US11339166B2 (en) 2022-05-24
BR112020010364A2 (pt) 2021-01-26
JP7326276B2 (ja) 2023-08-15
CN111433200B (zh) 2024-03-22
KR102720958B1 (ko) 2024-10-24
EP3717471A1 (en) 2020-10-07
MA51200A (fr) 2020-10-07
MX2020005423A (es) 2020-08-27
IL274938B1 (en) 2023-01-01
EP3717471B1 (en) 2022-01-05
WO2019105886A1 (en) 2019-06-06
US20210101903A1 (en) 2021-04-08
PH12020550725A1 (en) 2021-02-15
CO2020008066A2 (es) 2020-08-31
CA3084090A1 (en) 2019-06-06
ZA202004025B (en) 2021-09-29
PL3717471T3 (pl) 2022-03-21
CY1125044T1 (el) 2023-03-24
AU2018374456A1 (en) 2020-07-16
US12065443B2 (en) 2024-08-20
KR20200096571A (ko) 2020-08-12
TW201930301A (zh) 2019-08-01
CN111433200A (zh) 2020-07-17
SG11202004925QA (en) 2020-06-29
PT3717471T (pt) 2022-03-08
RU2020121645A3 (hu) 2022-03-01
IL274938A (en) 2020-07-30
DK3717471T3 (da) 2022-01-31
RU2020121645A (ru) 2022-01-04
JP2021505553A (ja) 2021-02-18
ES2908283T3 (es) 2022-04-28
US20220340581A1 (en) 2022-10-27
AU2018374456B2 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201720163D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
IL271807A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL261444A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL257336B (en) Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
PT3586832T (pt) Composição farmacêutica para o tratamento da obstipação
GB201720101D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201809836D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201503098D0 (en) Novel branimycin derivatives and pharmaceutical compositions thereof useful for the treatment of bacterial infectious diseases